Objectives: Antibiotic selective pressure may result in changes to antimicrobial susceptibility throughout the course of infection, especially for organisms that harbour chromosomally encoded AmpC b-lactamases, notably Enterobacter spp., in which hyperexpression of ampC may be induced following treatment with cephalosporins. In this study, we document a case of bacteraemia caused by a bla SME-1 -harbouring Serratia marcescens that subsequently developed resistance to expanded-spectrum cephalosporins, piperacillin/tazobactam and fluoroquinolones, over the course of several months of treatment with piperacillin/tazobactam and ciprofloxacin.
Introduction
De novo selection of antibiotic resistance through the course of antibiotic therapy is a well-documented event for Gram-negative bacteria that possess chromosomally encoded and inducible AmpC b-lactamases.
1 Notably, bacteraemia caused by Enterobacter spp. treated with an expanded-spectrum cephalosporin can lead to selection of mutants with derepressed expression of the ampC gene and clinical failure. 2, 3 Therefore, many recommend cefepime or a carbapenem for the treatment of AmpC-producing bacteria, as these b-lactams are poorly hydrolysed by AmpC. 4 However, carbapenemase-producing Enterobacteriaceae resistant to both cefepime and carbapenems are widespread throughout the world, resulting in few or no treatment options for these organisms. 5 In the USA, KPC is the most prevalent carbapenemase, although others, such as SME, are sporadically reported. 6 The SME carbapenemases are class A serine b-lactamases, identified, to date, only in Serratia marcescens. In contrast to other serine carbapenemases, SME enzymes are phenotypically unique, exhibiting poor hydrolytic activity against expanded-spectrum cephalosporins. [7] [8] [9] As such, isolates that harbour SME often test susceptible to ceftazidime or ceftriaxone, but resistant to ertapenem, imipenem, meropenem and aztreonam. [8] [9] [10] In addition, bla SME is chromosomal; isolates producing the enzyme do not typically express the same MDR profile seen in isolates with plasmidmediated carbapenemases such as bla KPC , which usually harbour genes conferring resistance to other antimicrobial classes on the same plasmid. To date, five SME variants have been described, SME-1 to SME-5 (NCBI, ftp://ftp.ncbi.nlm.nih.gov/pathogen/betalac tamases/Allele.tab).
Herein, we document a case of SME-producing S. marcescens bacteraemia. The isolate was initially susceptible to ciprofloxacin, expanded-spectrum cephalosporins and piperacillin/tazobactam, and the patient was treated with piperacillin/tazobactam and ciprofloxacin. Over the course of several months, the patient's isolates became resistant to these two agents in vivo. WGS elucidated the origins of this resistance and phenotypic, biochemical and gene expression studies demonstrated enhanced activity of both AmpC and SME enzymes in the resistant isolates.
Patients and methods

Case summary
A patient in their early forties with a history of alcoholic cirrhosis, oesophageal varices and hepatic encephalopathy presented to an outside hospital with nausea and haematemesis. The patient was haemodynamically unstable with an international normalized ratio of 10 and transferred to our institution for liver transplantation evaluation. Oesophagogastroduodenoscopy upon admission demonstrated gastric stricture. The patient remained haemodynamically stable until hospital day (HD) 7, when recurrent haematemesis and hypotension prompted banding of oesophageal varices. Ceftriaxone was started after the procedure and blood culture on HD 7 grew S. marcescens (isolate D-1) resistant to ertapenem, imipenem and meropenem, and susceptible to ceftriaxone, cefepime and piperacillin/tazobactam (Table 1) . Therapy was switched to piperacillin/tazobactam on HD 8 and was continued until liver transplantation on HD 26. Fever in association with T-tube dislodging prompted repeat blood cultures on HD 39 and a biliary repair procedure on HD 41. Blood cultures from HD 39 again grew S. marcescens (isolate D-2; Table 1 ) and the patient was treated with 15 days of piperacillin/tazobactam, adjusted for renal dysfunction (2.25 g intravenously q6h) and oral ciprofloxacin for 7 days. The patient developed delirium and repeated emesis on HD 90, which prompted a culture of the patient's Jackson-Pratt drain fluid, which yielded S. marcescens isolate D-3 (Table 1) , resistant to trimethoprim/sulfamethoxazole, ciprofloxacin and piperacillin/tazobactam. This isolate was deemed a colonizer and the patient was not treated. The patient was discharged to a skilled nursing facility on HD 125 and readmitted 13 days later for fever, hypotension and shortness of breath. The patient was intubated, started on two vasopressors, continuous renal replacement therapy and vancomycin and piperacillin/tazobactam. Blood cultures grew Escherichia coli and amikacin was added. Admission respiratory cultures grew S. marcescens and repeat blood cultures on HD 2 and HD 4 also grew S. marcescens. All S. marcescens isolated during this second hospitalization had identical susceptibility profiles to D-3 (not shown). Despite continued therapy with amikacin, ciprofloxacin and piperacillin/tazobactam, the patient's clinical condition deteriorated and the patient died on the sixth day of their second admission. The timeline of the patient's hospital course and isolation of each S. marcescens isolate is summarized in Figure 1 .
Methods
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed by broth microdilution in CAMHB, according to CLSI standards, 11 using panels prepared in-house. Antimicrobial susceptibility results were interpreted according to CLSI M100S 2017 breakpoints.
11
WGS
Isolates D-1, D-2 and D-3 were screened for the presence of bla SME by PCR amplification with published primer sets 6, 8 (Table S1 , available as Supplementary data at JAC Online) then subjected to WGS, as described elsewhere. 12 Briefly, genomic DNA was prepared using EZ1 Biorobot with DNA Tissue Kit (QIAGEN, Valencia, CA, USA). DNA sequencing was performed on an Illumina MiSeq platform (2%250 bp reads). Sequencing coverage among all isolates was between 140% and 200%. Illumina reads were assembled de novo using the A5 Pipeline 13 into larger contigs, which were annotated using RAST 14 and PATRIC. 15, 16 Raw reads were processed on a Galaxy server 17 using FASTQ Groomer, 18 followed by FASTQ Joiner 18 to match and merge paired reads. The CSI Phylogeny tool 19 was used to identify high-quality SNPs between isolates. Variant call format (VCF) files from CSI Phylogeny output were combined using the VCFcombine tool 20 on the Galaxy server. The combined VCF file was analysed and visualized using VariationBrowser software. 21 Whole genome alignment was performed on annotated merged contigs using progressive Mauve 22 and genomic differences and rearrangements were visualized using Geneious version 10.
23 WGS data were submitted to GenBank under BioProject accession number PRJNA381643 (BioSample accession numbers SAMN06685768, SAMN06685769 and SAMN06685770 for isolates D-1, D-2 and D-3, respectively). AmpC and SME-1 hyperproduction in Serratia marcescens JAC in Enterobacter cloacae 24 and the plasma concentration of imipenem at 2 h post-infusion in healthy volunteers. 25 As a positive control, the AmpCproducing S. marcescens isolate SC 9782 in an SME-negative background 26 was induced with cefoxitin (10 mg/L in PB) or treated with PB as a reference. After induction, centrifuged cell pellets were washed with PB; pelleted cells were suspended in 0.2 M acetate buffer, pH 5.5.
b-Lactamases were extracted from the cells following five freeze/thaw cycles (dry ice-ethanol bath/37 C water bath). The clarified supernatant containing periplasmic contents, including b-lactamases, was tested for b-lactamase activity. Protein concentrations were measured using the bicinchoninic acid (BCA) assay (Pierce BCA Protein Assay Kit, Thermo Fisher, Waltham, MA, USA). b-Lactamase activity in each extract was measured using a nitrocefin hydrolysis assay. To differentiate SME and AmpC activities, extracts were incubated for 2 min with either PB, to determine total blactamase activity (the sum of SME and AmpC activities), or 15 mg/L aztreonam, a concentration that inhibited AmpC activity by at least 95% under the conditions tested. Aztreonam is a potent AmpC inhibitor 27 with poor affinity for SME. 9 Prewarmed nitrocefin (500 mg/L in PB) was added to each extract after the incubation. Hydrolysis rates were measured at 490 nm with a BioTek5 plate reader (BioTek, Winooski, VT, USA) for 1-2 min using only the initial linear rate of reaction to determine nitrocefin hydrolysis/ min/ng of protein in triplicate assays. Hydrolysis rates corresponding to AmpC and SME activities were calculated from the nitrocefin hydrolysis rates of cell extracts in the presence and absence of aztreonam.
AmpC and SME transcription analysis
Colonies from overnight cultures of isolates D-1 and D3 were resuspended in 4 mL of LB broth (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) to a turbidity equivalent to that of a 1.0 McFarland standard and incubated at 35 C on a tube rocker for 2 h. Expression of AmpC-type b-lactamase genes bla SRT-2 and bla SME-1 was induced using imipenem for 2 h, a timepoint at which the ampC mRNA level in E. cloacae reaches its peak after induction with cefoxitin, 28 as described above. After induction, 200 lL of RNAProtect Bacteria Reagent (QIAGEN) was added to 100 lL of broth culture, followed by centrifugation at 5000 g for 10 min. RNA was extracted on the QIAcube platform (QIAGEN) using the RNeasy Mini Kit (QIAGEN). DNase treatment was performed using the TURBO DNA-free Kit (Life Technologies, Grand Island, NY, USA). RNA integrity and quantity were evaluated using the Agilent RNA 6000 Nano Kit on an Agilent 2100 Bioanalyzer instrument (Agilent Technologies, Santa Clara, CA, USA). cDNA synthesis with SuperScript IV VILO Master Mix (Life Technologies) was performed on the GeneAmp PCR System 9700 (Life Technologies) with 1 lg of total RNA.
Incubation time at 50
C was 20 min to maximize cDNA yields according to the manufacturer's instructions. Relative expression of ampC, bla SME and rpoB was quantified using real-time PCR. Each 20 lL PCR included 10 lL of TaqMan Fast Advanced Master Mix (Life Technologies), S. marcescens bla SRT-2 -, bla SME-1 -and rpoB-specific primers and probes (Table S1 ) at final concentrations of 500 and 250 nM, respectively, and 5 lL of diluted cDNA or a no-reverse transcriptase control to detect genomic DNA contamination. PCR was performed on a LightCycler V R 480 (Roche Diagnostics, Indianapolis, IN, USA) with the following settings: cDNA synthesis at 50 C for 2 min and initial denaturation at 95 C for 20 s, followed by 40 two-step cycles of 95 C for 3 s and 60 C for 30 s. Fluorescence was detected after the second step of each cycle. PCR efficiency for each target gene was determined using six 10-fold dilutions of cDNA and was used to calculate efficiency-adjusted ratios between bla SRT-2 and bla SME-1 to rpoB using the Advance Relative Quantification Module of the LightCycler V R 480 software (version 1.5.0 SP3; Roche Diagnostics). 29 Fold changes in gene expression between imipenem-induced and non-induced samples were calculated from these normalized ratios. Statistical analysis was performed in BioStat version 6 software 30 using two-tailed one-sample Student's t-test with a hypothetical mean of 1. The basal expression of both bla SRT-2 and bla SME-1 in D-3 compared with D-1 was calculated from efficiency-adjusted Ct values using the DDCt method, followed by statistical analysis using unpaired Student's ttest.
Results
Susceptibility profiles of the isolates investigated are shown in Table 1 . WGS performed on the isolates revealed bla SME-1 was located on a 28.4 kb genomic island called SmarGI1-1 31 (Figure 2 ), the only acquired antimicrobial resistance gene identified. In addition, all isolates harboured a bla SRT-2 AmpC-type b-lactamase gene. Comparative genomics of the isolates revealed the chromosomes of D-1 and D-2 were identical, with five non-conservative SNPs between these two isolates and isolate D-3 (Table 2) . Notably, a predicted mutation H61P was found in ampD and a mutation predicted to encode an early stop codon at position 226 was identified in another protein with the same putative function as ampD (Table 2) . Mutations predicted to encode S83R in the DNA gyrase subunit A gene gyrA and G60A in the transcriptional repressor sdeS were identified. The S83R gyrA mutation has been associated with fluoroquinolone resistance in S. marcescens, Hemarajata et al.
while mutations in sdeS are associated with overexpression of the SdeAB multidrug efflux pump, 34 whose main substrates include ciprofloxacin and chloramphenicol, but not b-lactams. Figure 3 ). In D-1, imipenem increased AmpC activity by 25.0-fold (from basal activity of 0.70 to 17.5 lmoles/min/ng post-induction) and SME-1 activity by 4.67-fold (from basal activity of 0.15 to 0.70 lmoles/min/ng post-induction) (Figure 3) . In D-3, addition of imipenem resulted in a 1.30-fold increase in AmpC activity (from basal activity of 97.7 to 127 lmoles/min/ng post-induction) and a 1.28-fold increase in SME-1 activity (from basal activity of 11.3 to 14.4 lmoles/min/ng post-induction).
mRNA expression was evaluated for bla SRT-2 and bla SME-1, normalized to that of the housekeeping rpoB gene. The basal expression of both b-lactamases in D-3 was significantly higher compared with that of D-1, with DDCt " #4.72+0.542 (P " 0.001) for bla SRT-2 and #3.53+0.216 (P , 0.0001) for bla SME-1 . The increased expression of these genes in D-3 compared with D-1 was also observed after imipenem induction, with DDCt " #4.36+0.613 (P " 0.0021) for bla SRT-2 and #3.06+0.254 (P " 0.0003) for bla SME-1 . When compared for imipenem-non-induced and -induced samples (Figure 4) , addition of imipenem to D-1 resulted in significant upregulation of bla SRT-2 and bla SME-1 mRNA by 3.29+0.62-fold (P " 0.0233) and 2.72+0.38-fold (P " 0.0155) that of non-induced samples. In contrast, imipenem induction did not result in a significant increase in bla SRT-2 or bla SME-1 (P " 0.45) expression in D-3, when evaluated by one-sample two-tail t-test (P " 0.44 and P " 0.45, respectively).
Discussion
Antimicrobial resistance is an evolutionary process that involves adaptation to the changing environment. 36 Selective pressure imposed by antibiotic therapy can lead to intra-host adaptation, including accumulation of de novo mutations or acquisition of genetic elements that confer resistance to antibiotics, providing an evolutionary advantage to the resistant population. 37, 38 There have been a limited number of longitudinal studies that utilized both phenotypic testing and WGS to examine temporal acquisition of antimicrobial resistance among Enterobacteriaceae isolated from patients undergoing antibiotic treatment. 39, 40 Herein, we demonstrated emergence of ceftriaxone and piperacillin/tazobactam resistance, as a result of AmpC and SME-1 derepression in a case of carbapenem-resistant S. marcescens bacteraemia treated with piperacillin/tazobactam. Derepression of AmpC in S. marcescens Figure 2 . Chromosomal genomic island containing bla SME-1 identified by WGS in all three isolates. 
AmpC and SME-1 hyperproduction in Serratia marcescens JAC during treatment is reportedly low (0%-7%), 3, 24, 41 in particular when compared with Enterobacter spp., in which emergence of resistance is more common (8.3%-19%) . 3, [42] [43] [44] piperacillin/tazobactam has infrequently been associated with selection of resistance due to derepression of chromosomal AmpC in S. marcescens, 3, 41 but is the most likely cause for selection of stably derepressed mutants herein. Although piperacillin and ceftriaxone are poor substrates for the AmpC and SME-1 enzymes, they will be affected by derepression of the two enzymes. 45 Thus, this case demonstrates a clinical challenge, as the isolate was resistant to the carbapenems as a result of its SME-1 enzyme, leaving few treatment options.
Unsurprisingly, gene expression and b-lactamase activity studies demonstrated a constitutive, high-level expression of ampC (bla SRT-2 ) in isolate D-3, the isolate in which we identified ampD mutations; in addition, we observed a similar phenotype for bla SME-1, which may also be associated with an ampD mutation. The ampD gene encodes a cytoplasmic amidase that hydrolyses muropeptides, which accumulate after exposure to b-lactams and bind the regulatory protein AmpR, resulting in increased expression of ampC. 46 Conversely, ampD expression decreases the intracellular concentration of muropeptide, leading to downregulation of ampC expression. 47, 48 Mutations in the ampD gene that affect its amidase function are the most common cause of constitutive hyperproduction of AmpC, due to accumulation of muropeptides in the cytoplasm. 1 Regulation of SME gene expression is less well understood. A LysR-family transcriptional regulator SmeR, located directly upstream to the bla SME-3 gene, has been shown to be a weak inducer of bla SME-3 in the presence of imipenem. 49 However, the entire genomic island carrying bla SME-1 and smeR were identical for all isolates in this study, suggesting that the constitutively high levels of bla SME-1 expression and activity in D-3 were due to elements outside this genomic island. The SmeR amino acid sequence shares 66% sequence identity to that of NmcR, also a LysR-family transcriptional regulator first identified in E. cloacae. 24, 49 NmcR regulates the expression of nmcA, a gene that encodes a serine carbapenemase found in E. cloacae. Interestingly, mutations in ampD were also associated with derepression of NmcA. 24 Considering the homology between smeR and nmcR, it is possible that the ampD mutations in D-3 resulted in derepression of SME-1. However, this hypothesis requires further confirmation.
In conclusion, our study described an unusual temporal acquisition of resistance to expanded-spectrum cephalosporins in S. marcescens isolates from a single patient during the course of antimicrobial treatment. Although emergence of in vivo resistance to expanded-spectrum cephalosporins during treatment of S. marcescens infection has been reportedly low, clinical microbiology laboratories and physicians should be aware of this possibility and perform susceptibility testing on sequential S. marcescens isolates to detect resistance that may have developed over the course of antimicrobial treatment. 
